ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera

ALX Oncology (ALXO) announced new data from a Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals’ (JAZZ) Ziihera in heavily pretreated patients with metastatic breast cancer. The topline findings, from an exploratory analysis in this trial, indicate that among patients with confirmed HER2-positive mBC, CD47 expression is predictive of evorpacept activity. “These new findings support a CD47-dependent, HER2-driven biology for evorpacept,” said Barbara Klencke, M.D., Chief Medical Officer at ALX Oncology. “Going forward, we believe that a biomarker-driven approach incorporating CD47 expression may optimize patient selection for evorpacept combinations with HER2-targeted agents. Additionally, taken together, the data from this trial and the ASPEN-06 clinical trial reinforce our confidence in the ongoing ASPEN-09-Breast Phase 2 trial.”